Are you interested in DNA methylation for biomarker discovery or clinical use cases? Check out this video from our joint Co-Lab session with Oxford Nanopore Technologies, presented at the American Society of Human Genetics: "From Arrays to Sequencing: Enhancing Methylation Analysis for Biomarker Discovery and Clinical Applications". In this session, Wasatch Biolabs’ Tim Jenkins, PhD, and Jonathon Hill, PhD announce the launch of Direct Whole Methylome Sequencing (dWMS). They explore its potential to shape the future of methylation research and clinical epigenomics with Oxford Nanopore’s Kathleen C. Barnes, PhD. Key takeaways: —The shift from arrays to sequencing drives deeper methylation insights for multi-omics analyses. —These enhanced insights are directly applicable to biomarker discovery and clinical research. —Together, these advancements are paving the way for precision medicine. Whether your focus is translational research or clinical development, follow the link below to explore the future of epigenomics and multi-omic innovation. Watch the full video here: https://lnkd.in/ge-mrUrf #Epigenomics #Methylation #NGS #BiomarkerDiscovery #PrecisionMedicine #OxfordNanoporeTechnologies?
Wasatch Biolabs
生物技术研究
Heber City,UT 1,123 位关注者
Changing the way medical diagnostics are performed.
关于我们
Wasatch BioLabs is an independent biotechnology company with an innovative approach to diagnostics. Our team of experts is transforming diagnostics testing and pushing the boundaries of what’s possible in biotechnology. Offering world class laboratory services, testing, and results, Wasatch BioLabs is driven by a core mission–to completely change the way medical diagnostics is performed. So, whether you’re a biotech company or a research institution, trust Wasatch BioLabs for your testing needs.
- 网站
-
www.wasatchbiolabs.com
Wasatch Biolabs的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Heber City,UT
- 类型
- 私人持股
- 创立
- 2022
地点
-
主要
321 W 1300 S
Suite 130
US,UT,Heber City,84032
Wasatch Biolabs员工
动态
-
Congratulations to our parent company, Renew Biotechnologies, for winning the BioTech Breakthrough Award for DNA Sequencing Innovation of the Year! #DNASequencing #Methylation #Epigenetics #Diagnostics #BiotechInnovation?
Honored to receive the BioTech Breakthrough Award for “DNA Sequencing Innovation of the Year.” This award highlights our robust and evolving technology ecosystem, which serves as the foundation for innovation across Renew’s diverse portfolio, including neurodegenerative diseases, women’s health, pathogen detection, and more. Through Wasatch Biolabs, a Renew Biotechnologies subsidiary and high-throughput clinical laboratory, we are excited to also offer our sequencing applications for third-party use. This allows diagnostic companies, healthcare institutions, and other organizations to deliver groundbreaking tests that enhance patient care and outcomes. Explore the full list of 2024 Biotech Breakthrough Award winners here: https://lnkd.in/gYXC6PQ5 To read the full press release, visit: https://lnkd.in/gmtgHw2J #BiotechInvestment #Innovation #Diagnostics #RenewBiotechnologies #WasatchBiolabs #PrecisionHealthcare
-
Wasatch Biolabs is excited to introduce MethylSeqR, an exclusive R package that makes native-read methylation data more accessible. With MethylSeqR, researchers can analyze methylation across the entire genome, covering up to 30X more CpG sites than traditional arrays. Designed to simplify the transition from methylation array to direct Whole Methylome Sequencing, MethylSeqR integrates seamlessly into existing array-based workflows. With no bioinformatics expertise required, users can perform key analyses with just four simple commands, including: —Methylation summary by base position or CpG Islands —Differential expression by region, read, or position —Sliding window analysis Only available to WBL clients, contact our team today to explore how MethylSeqR can be incorporated into your research projects! Link: https://lnkd.in/gB6nRYQz #MethylSeqR #directWholeMethylomeSequencing #Methylation #Epigenetics?
GitHub - Wasatch-BioLabs/MethylSeqR: R package for DNA methylation analysis on Direct Whole Methylome Sequencing (dWMS) data.
github.com
-
Excited to be featured on the Empowered Patient Podcast with Karen Jagoda! Unlike DNA sequence, which largely remains constant throughout life, epigenetic markers change due to aging, disease, and other factors, making them attractive diagnostic targets. Dr. Jonathon Hill, PhD explores the clinical potential of our novel DNA methylation technologies for early disease detection and other applications. Listen below or on any podcast streaming platform: https://lnkd.in/gscCwUEv #Diagnostics #EpigeneticMedicine #PrecisionMedicine #Diagnostics #AlzheimersDisease #DNASequencing #Methylation #OxfordNanoporeTechnologies #NativeSequencing
#transcript Dr. Jonathon Hill Wasatch Bio Labs #NextGenSequencing 3.0 platform analyzes blood to detect epigenetic changes provide insights into current health & predisposition for diseases. Third-generation sequencing can provide longer sequence reads & analyze epigenetic modifications to DNA.?Epigenetics can change over time in response to diet, environment & lifestyle. Advanced genetic testing has the potential to provide biomarkers to support personalized medicine for earlier detection & tailored interventions.#GeneticTesting #Epigenetics #GeneticResearch #PersonalizedMedicine #DNAInnovation #BiotechBreakthroughs #GeneRegulation #HealthcareInnovation #FutureofMedicine https://lnkd.in/gN9cqQZs
Third-Generation Sequencing Unlocks Insights Into Epigenetics and Biomarkers with Dr. Jonathon Hill Wasatch Bio Labs TRANSCRIPT
empoweredpatientradio.com
-
A big thank you to Dasha Tyshlek for hosting us on the Biomedical Frontiers Podcast! In this episode, Dr. Jonathon Hill, PhD, Wasatch Biolabs Co-Founder, dives into our proprietary methylation technologies and their potential to accelerate biomarker discovery and clinical impact through partnerships across therapeutic areas. Tune in at the link below or on any other podcast platform: https://lnkd.in/gtez3fVT #Methylation #NanoporeSequencing #NativeSequencing #ClinicalEpigenomics #BiomarkerDiscovery?
Genetics researchers reached a monumental milestone in 2000 when they laid out the ATCG sequence of our DNA. But that is only a part of the story in understanding disease. More recently, we have learned how epigenetic changes, like chemical modifications in DNA, add another layer of complexity, showing how lifestyle and environmental factors can impact gene expression over time. Jonathon Hill Ph.D, shares how his teams at Brigham Young University and Wasatch Biolabs are developing a multitude of new epigenetic tests for early detection of disease, treatment monitoring, and health prediction using novel sequencing techniques at scale. Listen: https://lnkd.in/evmCeHB3 #podcast #biotech #biotechnews #newresearch #precisionmedicine
-
Big milestone for Wasatch Biolabs! Looking forward to future breakthroughs in methylation research and clinical epigenomics. https://lnkd.in/ePyqZGf8 #Innovation #Methylation #Research #ClinicalEpigenomics
Wasatch BioLabs and Oxford Nanopore Team Up to Accelerate Methylation Sequencing Towards Clinical Use | Oxford Nanopore Technologies
nanoporetech.com
-
Thrilled about the innovation this collaboration with Oxford Nanopore Technologies will bring! Join us for our joint WBL x Oxford Nanopore CoLab session at the upcoming Annual Meeting of the American Society of Human Genetics in Denver. Date and time: Nov 6th at 12pm MT Location: Colab Theater #1 WBL Booth: #404 #DirectWholeMethylomeSequencing #ClinicalEpigenomics #DNA #Sequencing #Nanopore #Innovation
Excited to announce a collaboration with Wasatch Biolabs (WBL) to develop a Direct Whole Methylome Sequencing product that addresses key limitations associated with traditional bisulfite sequencing and methylation microarrays. This collaboration is designed to build on Wasatch BioLab’s existing proprietary methylation assays and create market-leading offers to drive innovation in genomic and epigenomic analysis, accelerating breakthroughs in research and clinical applications. Learn more: https://lnkd.in/ePyqZGf8
-
Our CEO, Chad Pollard, had the exciting opportunity to showcase?Wasatch Biolabs proprietary sequencing technology at Oxford Nanopore Technologies #NCM2024 meeting! Chad's talk highlighted some of WBL's novel methylation assays and their potential in biomarker discovery and clinical diagnostics, with a focus on tests for neurodegenerative disease screening and male infertility. Watch the full presentation https://lnkd.in/dQaASH5j or visit www.wasatchbiolabs.com to learn how WBL’s technology is shaping the future of epigenetic research and precision diagnostics. #NanoporeConf #BioPharmaDay #Methylation #DNASequencing #PrecisionMedicine
NESSI-Seq novel cfDNA methylation assays for biomarker discovery and precision medicine
https://www.youtube.com/
-
Unlock the Full Potential of Liquid Biopsies! Cell-free DNA-based liquid biopsies have incredible diagnostic potential. However, research tools and clinical applications have been hindered by the challenge of highly fragmented, low concentration cfDNA. To solve this and bypass the limitations of traditional bisulfate sequencing, WBL has developed NESSI-Seq, a novel sequencing technique that preserves DNA in its native state to produce genomic and epigenomic data with unparalleled accuracy, sensitivity, and quality. Check-out our most recent white-paper to learn more!
-
Next generation sequencing (NGS) liquid biopsies are transforming clinical diagnostics. Circulating cell-free DNA (cfDNA) is a particularly versatile target for liquid biopsies, with rapidly expanding use cases for cancer, prenatal testing, pathogen detection, and beyond. But despite advancements in NGS technologies and DNA analysis, cfDNA-based liquid biopsies are significantly limited by low specificity, sensitivity, and complicated data interpretation. Check out our latest article exploring the pivotal role of NGS in liquid biopsies. We dive into the technological advancements propelling the global NGS market and precision medicine, examine future clinical outlooks, and discuss current limitations. This sets the stage to introduce Wasatch Biolabs' proprietary sequencing technologies. Find the full article here: https://lnkd.in/gvMJXEHJ #PrecisionMedicine #LiquidBiopsy #WBL #NGS #cfDNA #OxfordNanoporeTechnology
NGS Liquid Biopsy Technologies: Transforming Clinical Diagnostics
wasatchbiolabs.com